Live feed09:00:00·8dPRReleasevia QuantisnowAIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen® in Pancreatic Cancer, Backed by Positive Clinical Signals, Orphan Drug Status, and Global IPByQuantisnow·Wall Street's wire, on your screen.AIM· AIM ImmunoTech Inc.Health Care
